News and Press Releases
Research | CFTR Modulators FDA Approves Expansion of Modulators for People With Certain Rare Mutations

The U.S. Food and Drug Administration (FDA) today expanded its approval of three CFTR modulators to include additional people with CF who have certain rare mutations. The approval enables more than 600 individuals with CF who were not previously eligible for modulators to access drugs that treat the underlying cause of their disease for the first time.

| 3 min read
About the CF Foundation | Get Involved CF Foundation busca la participación de las comunidades afroamericana, latina, indígena, asiática, de Medio Oriente y otras personas de color

Poner atención a la diversidad de voces es fundamental a medida que continuamos con  nuestra meta de escuchar, aprender y actuar contra el racismo y la discriminación.

| 4 min read
About the CF Foundation | Get Involved CF Foundation Seeks Input from Communities of Color

Hearing from diverse voices is critical as we continue our journey to listen, learn, and take action against racism and discrimination.

| 3 min read
CFTR Modulators | About the CF Foundation A Message From Our CEO

The CF Foundation has successfully completed a sale of its remaining stake in royalties related to Vertex's CFTR modulators for an upfront payment of $575 million and a potential future payment of $75 million, bringing additional resources to the fight against CF.

| 3 min read
Research | CFTR Modulators Roche Acquires Potential CF Therapies; Plans to Develop Alternatives to CFTR Modulators

Roche has acquired a set of potentiator compounds from Enterprise Therapeutics and intends to study them for the treatment of CF. The Cystic Fibrosis Foundation previously provided funding to Enterprise to develop these potential medicines.

| 3 min read